Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once
weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to
beginning their standard therapy for their specific disease. The primary objective of this
study is to identify biomarkers of temsirolimus activity.